Key Takeaways From ADMA Biologics Analyst Ratings

adma biologics分析师评级要点

Benzinga · 2024/10/14 20:01 · 评级/大行评级

Throughout the last three months, 4 analysts have evaluated ADMA Biologics (NASDAQ:ADMA), offering a diverse set of opinions from bullish to bearish.

过去三个月来，有4位分析师对adma biologics（纳斯达克：ADMA）进行了评估，提出了从看好到看淡的不同意见。

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

在下表中，您将找到他们最近的评级摘要，揭示了过去30天内情绪的变化，并将它们与前几个月进行比较。

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $20.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 20.63% from the previous average price target of $15.75.

分析师评估的12个月价格目标揭示了更多见解，平均目标为19.0美元，最高估值为20.00美元，最低估值为18.00美元。目前的平均值已经上升了20.63%，从之前的15.75美元的平均价格目标。

Analyzing Analyst Ratings: A Detailed Breakdown

分析分析师评级：详细剖析

The perception of...

通过最...

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Key Takeaways From ADMA Biologics Analyst Ratings

Key Takeaways From ADMA Biologics Analyst Ratings

风险及免责提示

声明